Aiming for complete responses in renal-cell carcinoma
Mené sur 55 patients atteints d'un cancer rénal à cellules claires de stade avancé, cet essai de phase Ib évalue la dose maximale tolérée, l'activité antitumorale et la toxicité de l'avélumab, un anticorps monoclonal anti-PD-L1, en combinaison avec l'axitinib, un inhibiteur des récepteurs du VEGF, en traitement de première ligne
Treatments for metastatic renal-cell carcinoma have evolved rapidly in the past decade, and since 2006, targeted therapies have been the cornerstone of treatments, with pazopanib or sunitinib leading to objective responses in 24–31% of patients.1 Deep tumour responses have been described as a surrogate measure for overall survival in patients with renal-cell carcinoma.2 However, because these are rarely achieved with current standard first-line targeted therapies, novel tyrosine-kinase inhibitors (TKIs) are being tested.
The Lancet Oncology , commentaire, 2017